ERBB2 and breast cancer: Nevertheless, our study revealed that breast cancer patients with the HR+/HER2- molecular subtype who underwent neoadjuvant therapy using a treatment regimen consisting of both chemotherapy and immune checkpoint inhibitors therapy did not exhibit any significant statistical variation in pathological complete response (PCR) as compared to patients who only received chemotherapy.